FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Zacks Investment Research • Aug 5, 2026

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again

Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to ​focus on a fresh disappointment in U.S. patient volumes ‌and the management's decision to merely confirm, not raise, the full-year guidance.

Reuters • Aug 4, 2026

Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.

MarketBeat • Aug 4, 2026

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 4, 2026

Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further

Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.

WSJ • Aug 4, 2026

Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook

Fresenius Medical Care on Monday reported second-quarter operating income well ahead of ​market expectations and reaffirmed its full-year outlook, ‌as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient ​treatment volumes.

Reuters • Aug 3, 2026

Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.

Proactive Investors • Jul 23, 2026

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth

Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.

Seeking Alpha • Jul 21, 2026

Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows

FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.

Seeking Alpha • Jul 11, 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.

Zacks Investment Research • Jul 8, 2026